Cargando…

Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer

INTRODUCTION: To investigate the factors that affect the choice of 5-fluorouracil (5-FU) or its oral alternative, capecitabine, as first-line treatment in patients with colorectal cancer (CRC). METHODS: Patients treated with 5-FU or capecitabine for CRC between January 1, 2011 and December 31, 2013...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bloem, Lourens T., De Abreu Lourenço, Richard, Chin, Melvin, Ly, Brett, Haas, Marion
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315063/ https://www.ncbi.nlm.nih.gov/pubmed/28261643 http://dx.doi.org/10.1007/s40487-016-0020-4

Ejemplares similares

The choice of first-line Chronic Myelogenous Leukemia treatment
por: Fava, Carmen, et al.
Publicado: (2015)

Optimizing the first-line treatment for metastatic colorectal cancer
por: Cherri, Sara, et al.
Publicado: (2023)

Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation
por: Rossi, Luigi, et al.
Publicado: (2013)

Impact of first-line treatment choice on long-term outcomes of hyperthyroid Graves’ disease patients with thyrotoxic periodic paralysis
por: Karndumri, Krittadhee, et al.
Publicado: (2020)

Controversies in colorectal cancer: First line treatment with epidermal growth factor inhibitors and RAS in 2014
por: Junior, Gilberto de Lima Lopes
Publicado: (2014)

Stem cell transplantation in aplastic anemia: Impact on choices for first line therapy
por: Bacigalupo, Andrea, et al.
Publicado: (2019)

Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options
por: Meloni, Seema T, et al.
Publicado: (2017)

Glycemic Control and Factors Impacting Treatment Choice in Tubeless Insulin Pump Users: A Survey of the T1D Exchange Glu Online Community
por: Layne, Jennifer E., et al.
Publicado: (2019)

Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer
por: Braun, M S, et al.
Publicado: (2003)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009)

First-Line Maintenance Treatment in Metastatic Colorectal Cancer (mCRC): Quality and Clinical Benefit Overview
por: Martín-Richard, Marta, et al.
Publicado: (2021)

The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer
por: Fernández Montes, Ana, et al.
Publicado: (2023)

Non–Small Cell Lung Cancer Patient Preferences for First-Line Treatment: A Discrete Choice Experiment
por: MacEwan, Joanna P., et al.
Publicado: (2020)

Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment
por: González, Juan Marcos, et al.
Publicado: (2017)

FOLFIRI(®) and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms
por: Bécouarn, Yves, et al.
Publicado: (2014)

Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer
por: Derksen, Jeroen W G, et al.
Publicado: (2019)

Is imatinib still the best choice as first-line oral TKI
por: Bansal, Shweta
Publicado: (2014)

Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer
por: Feliu, J, et al.
Publicado: (2004)

Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2011)

Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
por: Molina-Garrido, M J, et al.
Publicado: (2011)

Network Meta-analysis of First-Line Systemic Treatment for Patients With Metastatic Colorectal Cancer
por: Xu, Shan, et al.
Publicado: (2021)

Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
por: Rong, Xuetong, et al.
Publicado: (2022)

Personalizing first-line treatment in advanced colorectal cancer: Present status and future perspectives
por: Motta, Rodrigo, et al.
Publicado: (2021)

Angiotensin converting enzyme inhibitors remain the first treatment of choice
por: Oh, Pyung Chun, et al.
Publicado: (2016)

Immune status at pre-treatment impacts on progression-free survival of metastatic colorectal cancer patients treated with first-line chemotherapy
por: Tada, Kohei, et al.
Publicado: (2015)

Combination of CNTs with Classical Drugs for Treatment in Human Colorectal Adenocarcinoma (HT-29) Cell Line
por: Abreu, Sara, et al.
Publicado: (2023)

Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer
por: García-Alfonso, P, et al.
Publicado: (2010)

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
por: Patel, Shiven B, et al.
Publicado: (2015)

Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial
por: Petracci, Elisabetta, et al.
Publicado: (2020)

Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment
por: Yong, Candice, et al.
Publicado: (2022)

Treatment of Metastatic Colorectal Carcinoma with Bevacizumab in First-Line and beyond First Progression: The KORALLE Non-Interventional Cohort Study
por: Arnold, Dirk, et al.
Publicado: (2022)

Professionals’ Treatment Preferences in the Prodromal Phase of Parkinson’s Disease: A Discrete Choice Experiment
por: van den Heuvel, Lieneke, et al.
Publicado: (2022)

FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping
por: Yeh, Yung-Sung, et al.
Publicado: (2014)

PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer
por: Mineur, L., et al.
Publicado: (2020)

Efficacy of electroconvulsive therapy as a potential first-choice treatment in treatment-resistant depression (Review)
por: Trifu, Simona, et al.
Publicado: (2021)

First choice
por: Wilson, Ken
Publicado: (2007)

Study on Allopathic and Alternative Treatments of Asthma and Factors Influencing Treatment Choices
por: Farooq, Javeria, et al.
Publicado: (2022)

Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer
por: Rao, S, et al.
Publicado: (2004)

Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study
por: Feliu, J, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_mpvkalkrourgo70lu76bql62ov